Stock Analiz

NewAmsterdam Pharma Co N.V. (NAMS) stock forecast and price target

Price $20.14 · data as of November 13, 2026

12-month price target

Average target$50.11
Upside / downside+148.8%
Analysts15
ConsensusStrong buy
Low $37.56Average $50.11High $60.29

Gold marker: average target · white marker: today’s price ($20.14)

Analyst ratings

Strong buy 3Buy 12Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-1.33+8.8%$35M
Next fiscal year
ends December 31, 2027
$-1.90−39.1%$43M
Next quarter
ends December 31, 2026
$-0.41+24.0%$12M
Quarter after
ends March 31, 2027
$-0.49−43.5%$1M

Consensus of the analysts covering NewAmsterdam Pharma Co, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.

Frequently asked questions

What is the NewAmsterdam Pharma Co stock price target?

The average 12-month target from 15 analysts is $50.11, 148.8% above the current price of $20.14 Targets range from $37.56 to $60.29.

Is NewAmsterdam Pharma Co a buy according to analysts?

The consensus rating is “Strong buy” (3 strong buy, 12 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is NewAmsterdam Pharma Co expected to earn?

Analysts expect EPS of $-1.33 for the fiscal year ending December 31, 2026 and $-1.90 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.